[go: up one dir, main page]

WO2009063215A3 - Use of crth2 antagonist compounds - Google Patents

Use of crth2 antagonist compounds Download PDF

Info

Publication number
WO2009063215A3
WO2009063215A3 PCT/GB2008/003843 GB2008003843W WO2009063215A3 WO 2009063215 A3 WO2009063215 A3 WO 2009063215A3 GB 2008003843 W GB2008003843 W GB 2008003843W WO 2009063215 A3 WO2009063215 A3 WO 2009063215A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonist compounds
crth2 antagonist
allergic
compounds
crth2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2008/003843
Other languages
French (fr)
Other versions
WO2009063215A2 (en
Inventor
Michael George Hunter
Eric Roy Pettipher
Colin Michael Perkins
Mark Anthony Payton
Luzheng Xue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxagen Ltd
Original Assignee
Oxagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxagen Ltd filed Critical Oxagen Ltd
Publication of WO2009063215A2 publication Critical patent/WO2009063215A2/en
Publication of WO2009063215A3 publication Critical patent/WO2009063215A3/en
Priority to US12/779,638 priority Critical patent/US20110124683A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to compounds of general formula (I): wherein R1, R2, R3, R4 and R5 are as defined herein for desensitising the immune system of a subject to allergens, thus preventing or reducing the symptoms of allergic conditions such as allergic asthma, allergic rhinitis or atopic dermatitis.
PCT/GB2008/003843 2007-11-13 2008-11-13 Use of crth2 antagonist compounds Ceased WO2009063215A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/779,638 US20110124683A1 (en) 2007-11-13 2010-05-13 Use of CRTH2 Antagonist Compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0722216.9A GB0722216D0 (en) 2007-11-13 2007-11-13 Use of crth2 antagonist compounds
GB0722216.9 2007-11-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/003824 Continuation-In-Part WO2009063202A2 (en) 2007-11-13 2008-11-13 Use of crth2 antagonist compounds

Publications (2)

Publication Number Publication Date
WO2009063215A2 WO2009063215A2 (en) 2009-05-22
WO2009063215A3 true WO2009063215A3 (en) 2009-08-27

Family

ID=38896181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/003843 Ceased WO2009063215A2 (en) 2007-11-13 2008-11-13 Use of crth2 antagonist compounds

Country Status (2)

Country Link
GB (1) GB0722216D0 (en)
WO (1) WO2009063215A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2009099902A1 (en) 2008-02-01 2009-08-13 Amira Pharmaceuticals, Inc. N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
EP2257536A4 (en) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc Cyclic diaryl ether as antagonists of prostaglandin d2 receptors
JP2011518130A (en) 2008-04-02 2011-06-23 アミラ ファーマシューティカルズ，インク． Aminoalkylphenyl antagonist of prostaglandin D2 receptor
US8501959B2 (en) 2008-06-24 2013-08-06 Panmira Pharmaceuticals, Llc Cycloalkane[B]indole antagonists of prostaglandin D2 receptors
EA019351B1 (en) 2008-07-03 2014-03-31 ПАНМИРА ФАРМАСЬЮТИКАЛС, ЭлЭлСи Antagonists of prostaglandin dreceptors
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
WO2010142934A1 (en) * 2009-06-12 2010-12-16 Pulmagen Therapeutics (Asthma) Limited Indole derivatives as ligands of crth2 receptors
CA2768492A1 (en) 2009-07-31 2011-02-03 Panmira Pharmaceuticals, Llc Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
WO2011017201A2 (en) 2009-08-05 2011-02-10 Amira Pharmaceuticals, Inc. Dp2 antagonist and uses thereof
CN102812000A (en) 2010-01-06 2012-12-05 潘米拉制药公司 Dp2 Antagonist And Uses Thereof
US8697869B2 (en) 2010-03-22 2014-04-15 Actelion Pharmaceuticals Ltd. 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US20130052190A1 (en) * 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
SG193902A1 (en) 2011-04-14 2013-11-29 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
SG11201402796SA (en) * 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
UA117780C2 (en) 2014-03-17 2018-09-25 Ідорсія Фармасьютікалз Лтд AZAINDOLACETIC ACID DERIVATIVES AND THEIR APPLICATIONS AS MODULATORS OF PROSTAGLANDIN D2 RECEPTORS
TW201620909A (en) 2014-03-18 2016-06-16 艾克泰聯製藥有限公司 Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
MX379014B (en) 2015-09-15 2025-03-10 Idorsia Pharmaceuticals Ltd CRYSTALLINE FORMS.
WO2017104728A1 (en) * 2015-12-16 2017-06-22 国立大学法人東京大学 Medicine for treating food allergy
ES2906887T3 (en) * 2016-07-21 2022-04-20 Chia Tai Tianqing Pharmaceutical Group Co Ltd Indole derivative used as a CRTH2 inhibitor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044260A1 (en) * 2003-10-23 2005-05-19 Oxagen Limited Use of crth2 antagonist compounds in therapy
WO2006092579A1 (en) * 2005-03-01 2006-09-08 Oxagen Limited Microcrystalline ( 5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid
WO2006095183A1 (en) * 2005-03-11 2006-09-14 Oxagen Limited 1-acetic acid-indole derivatives with pgd2 antagonist activity
WO2007107772A1 (en) * 2006-03-22 2007-09-27 Oxagen Limited Salts with crth2 antagonist activity
WO2008012511A1 (en) * 2006-07-22 2008-01-31 Oxagen Limited Compounds having crth2 antagonist activity

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005044260A1 (en) * 2003-10-23 2005-05-19 Oxagen Limited Use of crth2 antagonist compounds in therapy
WO2006092579A1 (en) * 2005-03-01 2006-09-08 Oxagen Limited Microcrystalline ( 5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid
WO2006095183A1 (en) * 2005-03-11 2006-09-14 Oxagen Limited 1-acetic acid-indole derivatives with pgd2 antagonist activity
WO2007107772A1 (en) * 2006-03-22 2007-09-27 Oxagen Limited Salts with crth2 antagonist activity
WO2008012511A1 (en) * 2006-07-22 2008-01-31 Oxagen Limited Compounds having crth2 antagonist activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "View of NCT00290381 on 2006_02_10", CLINICALTRIALS.GOV ARCHIVE, 10 February 2006 (2006-02-10), XP002535100, Retrieved from the Internet <URL:http://clinicaltrials.gov/archive/NCT00290381/2006_02_10> *
ANONYMOUS: "View of NCT00697281 on 2008_06_12", CLINICALTRIALS.GOV ARCHIVE, 12 June 2008 (2008-06-12), XP002535101, Retrieved from the Internet <URL:http://clinicaltrials.gov/archive/NCT00697281/2008_06_12> *

Also Published As

Publication number Publication date
GB0722216D0 (en) 2007-12-27
WO2009063215A2 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
WO2009063215A3 (en) Use of crth2 antagonist compounds
WO2007146838A3 (en) Substituted phenyl acetic acids as dp-2 antagonists
WO2010033701A3 (en) Inhibitors of sphingosine kinase 1
WO2007143745A3 (en) Substituted phenyl acetic acids as dp-2 antagonists
WO2010031184A8 (en) Azaindole derivatives as crth2 receptor antagonists
WO2009080638A3 (en) Sulfamides as zap-70 inhibitors
WO2010142766A3 (en) Pyrimidine derivatives as zap-70 inhibitors
WO2011084553A3 (en) Compositions and uses of cis-1,1,1,4,4,4-hexafluoro-2-butene
NZ594854A (en) Low-molecular polysulfated hyaluronic acid derivative and medicine containing same
WO2010079431A3 (en) Compounds for the prevention and treatment of cardiovascular disease
WO2009043889A3 (en) Oxadiazole derivatives
WO2008030744A3 (en) Inhibitors of c-met and uses thereof
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
WO2009156462A3 (en) Organic compounds
WO2012177893A3 (en) Trpm8 antagonists and their use in treatments
WO2010030813A3 (en) Methods for inhibiting ocular angiogenesis
EP2185514A4 (en) Vinyl-aryl derivatives for inflammation and immune-related uses
WO2010007116A3 (en) Pyridons as pdk1 inhibitors
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2010018109A3 (en) Substituted aminotetralines
WO2009002423A3 (en) Polycyclic guanine derivatives and use thereof
WO2010115751A3 (en) Oxadiazole derivatives
WO2011056511A3 (en) 4,6-diaminopyrimidine stimulators of soluble guanylate cyclase

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08848850

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08848850

Country of ref document: EP

Kind code of ref document: A2